OneDigital Investment Advisors LLC Purchases Shares of 44,275 Insulet Corporation $PODD

OneDigital Investment Advisors LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, HoldingsChannel reports. The fund acquired 44,275 shares of the medical instruments supplier’s stock, valued at approximately $6,741,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its holdings in Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 64 shares during the period. Cresset Asset Management LLC boosted its position in Insulet by 7.3% during the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after acquiring an additional 177 shares during the last quarter. Cerity Partners LLC grew its holdings in Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after acquiring an additional 7,030 shares during the period. Sei Investments Co. grew its holdings in Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after acquiring an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina raised its position in shares of Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after acquiring an additional 791 shares in the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is owned by corporate insiders.

Insulet Stock Performance

NASDAQ PODD opened at $143.34 on Monday. The company has a market cap of $9.94 billion, a price-to-earnings ratio of 26.79, a P/E/G ratio of 1.13 and a beta of 1.10. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The business has a 50 day moving average price of $155.20 and a 200-day moving average price of $188.22. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same period last year, the business earned $1.17 EPS. Insulet’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities analysts expect that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet remains a long-term growth story: its Omnipod wearable insulin-delivery platform supports recurring revenue, while the company recently reported 23.5% year-over-year revenue growth, earnings above analyst expectations, and raised confidence in its full-year outlook. Why Insulet Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Multiple law firms are publicizing an August 31, 2026 deadline for investors to seek lead-plaintiff status in a pending federal securities class action. The announcements mainly solicit shareholder participation and do not establish liability or damages. Insulet Securities Fraud Lawsuit Deadline Alert
• Negative Sentiment: The litigation creates a significant near-term overhang. Complaints filed by investors allege that Insulet and certain executives made materially false or misleading statements concerning manufacturing controls and the safety and reliability of its insulin-delivery products. One notice specifically cites alleged defective cannula manufacturing that could have caused insulin under-delivery in millions of Omnipod devices. If substantiated, the claims could lead to financial costs, regulatory scrutiny, reputational damage, and weaker customer confidence. Insulet Securities Class Action Allegations

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PODD shares. Citigroup boosted their price objective on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Raymond James Financial reaffirmed an “outperform” rating and set a $180.00 target price on shares of Insulet in a research note on Thursday, August 6th. Robert W. Baird set a $175.00 target price on Insulet in a report on Thursday, August 6th. UBS Group dropped their price target on Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a research note on Thursday, August 6th. Finally, William Blair initiated coverage on Insulet in a report on Wednesday, May 20th. They set an “outperform” rating on the stock. Fourteen investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.